Filing Flows › Pfizer (PFE) › Q2 2026
Pfizer (PFE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Pfizer (PFE) reported revenue of $15.0B for the second quarter 2026 (Q2 2026), +3% from a year earlier and +4% from the quarter before. Operating margin was -4.3%, net loss $237M (1.6% of revenue).
Pfizer, Q2 2026: revenue $15.0B (+3% year over year), operating margin -4.3%, net loss $237M, operating cash flow $835M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.0B | +4% | +3% |
| Operating profit | −$644M | -120% | -121% |
| Net earnings | −$237M | -109% | -108% |
| Operating cash flow | $835M | -68% | — |
| Free cash flow | $302M | -86% | — |
What changed
Revenue was $15.0B in Q2 2026, up 3% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $0.64B, an operating margin of -4.3%. Total costs grew 35% against revenue growth of 3%. The fastest-growing cost line was Other operating costs (+181%). The quarter ended with a net loss of $0.24B, after a profit of $2.7B the previous quarter.
Operating cash flow was $0.83B. Non-cash charges added back $1.6B of depreciation and amortization and $0.25B of share-based compensation. Working capital and other items used $0.80B. Capital expenditures of $0.53B left free cash flow of $0.30B.
Questions
What was Pfizer's revenue in the second quarter 2026?
Pfizer (PFE) reported revenue of $15.0B for the second quarter 2026 (Q2 2026), +3% from a year earlier and +4% from the quarter before.
Was Pfizer profitable in the second quarter 2026?
Operating loss was $644M (-4.3% of revenue) and net loss $237M.
Source: Pfizer 10-Q on SEC EDGAR.